ERBB2 and breast cancer: Results from the Gene expression-based Outcome for Breast Cancer Online (GOBO) database showed that women with basal and HER2-positive tumors that had high PXDN expression had poorer distant metastasis free survival (DMFS) compared to women with low PXDN-expressing tumors (Supplementary Fig. 6b).